Drug‐drug interactions in pharmacologic management of gastroparesis

@article{Youssef2015DrugdrugII,
  title={Drug‐drug interactions in pharmacologic management of gastroparesis},
  author={Amir S. Youssef and Henry P. Parkman and Swati Nagar},
  journal={Neurogastroenterology \& Motility},
  year={2015},
  volume={27}
}
Gastroparesis is a disorder characterized by delayed gastric emptying due to chronic abnormal gastric motility. The treatment of the disease often entails the co‐administration of several classes of pharmacological agents. These agents may be metabolized via the same pathway. Inhibition or induction of a shared metabolic pathway leads to change in the systemic levels of prescribed drugs, possibly leading to undesired clinical outcomes. 
Symptomatic Management of Gastroparesis.
TLDR
Treatment options for symptoms of gastroparesis include nausea, vomiting, epigastric pain, early satiety, and weight loss, and dietary changes may improve symptoms in patients with mild disease. Expand
Chapter 34 – Gastrointestinal Drugs
TLDR
This review of the January–December 2015 publications addresses adverse reactions to gastrointestinal-related drugs: acid-impacting, anticonstipation, prokinetic, antidiarrheal, antispasmodic, antiemetic, and anti-inflammatory agents. Expand
Current and Emerging Medical Therapies for Gastroparesis
TLDR
This chapter will review current treatment options, upcoming promising medications, and some of the hurdles in advancing the field forward in gastroparesis. Expand
Diabetic gastroparesis: current challenges and future prospects
TLDR
Advances in therapeutic endoscopic intervention with gastric per-oral endoscopic pyloromyotomy have also been shown to improve gastric emptying and gastroparesis (GP) symptoms. Expand
Gastroparesis: a turning point in understanding and treatment
TLDR
Endoscopic pyloromyotomy appears promising over the short term, especially for symptoms of nausea and vomiting, but further controlled trials and identification of the appropriate subgroup with pyloric dysfunction and assessment of long-term outcomes are essential. Expand
Drug–resin drug interactions in patients with delayed gastric emptying: What is optimal time window for drug administration?
  • M. Camilleri
  • Medicine
  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2016
TLDR
The functions of the stomach and the kinetics of emptying of different food forms or formulations are reviewed to make recommendations on timing of medication administration in order to avoid intragastric drug interactions. Expand
Novel Diet, Drugs, and Gastric Interventions for Gastroparesis.
  • M. Camilleri
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2016
TLDR
There are several novel approaches to advance treatment of gastroparesis including diet, novel prokinetics, interventions on the pylorus, and novel forms of gastric electrical stimulation, including 5-HT4 receptor agonists, such as velusetrag; and the ghrelin agonist, relamorelin. Expand
Gastroparesis and Cancer-Related Gastroparesis
TLDR
In patients with cancer failing to respond to medical management, a percutaneous endoscopy-placed gastric tube for decompression with a jejunal extension feeding tube (PEG-J) can be used to reduce symptoms and provide nutrition. Expand
Treatment of gastroparesis with botulinum toxin in patient after allogenic bone marrow  transplantation.
TLDR
It was noted that pyloric injection of botulinum toxin can improve symptoms and gastric emptying in a patient following allogenic bone marrow transplantation. Expand
Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort
TLDR
The majority of patients remaining on treatment with domperidone experienced an improvement in symptoms of gastroparesis, particularly postprandial fullness, nausea, vomiting, and stomach fullness. Expand
...
1
2
...

References

SHOWING 1-10 OF 135 REFERENCES
Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics.
TLDR
The purpose of this review is to provide an update on the use of antiemetics, prokinetics, and tricyclics for the treatment for nausea and vomiting associated with gastroparesis. Expand
Novel therapeutic agents in neurogastroenterology: advances in the past year
  • M. Camilleri
  • Medicine
  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2014
There have been significant advances in understanding the pathophysiological mechanisms in patients with neurogastroenterological disorders including irritable bowel syndrome (IBS) and functionalExpand
Gastroparesis: Current Concepts and Management
TLDR
In refractory cases with severe weight loss, invasive therapeutics such as inserting a feeding jejunostomy tube, intrapyloric injection of botulinum toxin, surgical (partial) gastrectomy, and implantable gastric electrical stimulation are occasionally considered. Expand
Making a case for domperidone in the treatment of gastrointestinal motility disorders.
TLDR
There are very few treatment options currently available for patients with gastrointestinal motility disorders, especially patients with gastroparesis, and medical studies, trials and case reports demonstrate the superior efficacy of domperidone when compared with placebo and other pharmaceutical therapies available. Expand
Severe gastroparesis: new treatment alternatives.
  • H. Abrahamsson
  • Medicine
  • Best practice & research. Clinical gastroenterology
  • 2007
TLDR
In the last decade, gastric electrical stimulation (GES) with a fully implantable device has evolved as a promising treatment, with significant effects on nausea and vomiting in most patients with severe, drug-refractory diabetic gastroparesis and postsurgical gastropareis. Expand
Gastroparesis: current diagnostic challenges and management considerations.
TLDR
Treatment is multimodal and includes dietary modification, prokinetic and anti-emetic medications, and surgical interventions and might provide new hope to patients with refractory gastroparesis. Expand
Treatment of gastroparesis: a multidisciplinary clinical review
  • T. Abell, Vr. K. Bernstein, +12 authors A. Vinik
  • Medicine
  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2006
TLDR
To provide practical guidelines for treatment, this document covers results of published research studies in the literature and areas developed by consensus agreement where clinical research trials remain lacking in the field of gastroparesis. Expand
Treatment of patients with diabetic gastroparesis.
TLDR
An overview of the pathophysiology of DGP is presented, diagnostic testing with a discussion of emerging technology is reviewed, and the latest research in treatment options for DGP are presented. Expand
Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin.
  • M. Sekkarie
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1997
TLDR
Patients with chronic renal failure are often on multiple medications and are at risk for the development of adverse effects from drug interactions, and the role of the inhibition of cytochrome P-4503A4 in the occurrence of the arrhythmia is discussed. Expand
Domperidone: Review of Pharmacology and Clinical Applications in Gastroenterology
TLDR
The pharmacology, clinical application, and safety profile of domperidone are revisited to revisit the pharmacology and clinical application of this beneficial medication. Expand
...
1
2
3
4
5
...